{
    "nctId": "NCT05755581",
    "briefTitle": "Efficacy of Neoadjuvant Endocrine Therapy Compared to Chemotherapy in Breast Cancer Patients",
    "officialTitle": "Efficacy of Endocrine Therapy Compared to Chemotherapy as a Neoadjuvant Treatment for Patients With Hormone Receptor-positive and HER2-negative Breast Cancer.",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Female Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "BASIC_SCIENCE",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Clinical response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Any histological type of invasive breast cancer. All grades of breast cancer (I, II, III). ER-positive and/or PR-positive, HER2-negative breast cancer. ER and/or PR level of positivity \u226534 % (score 4 according to modified Allred score).\n\nClinical Stages: any T N1-3, or T2-4 any N, M0.\n\nExclusion Criteria:\n\n* Hormone receptor positivity \\< 34%. inflammatory breast cancer Metastatic breast cancer. Recurrent breast cancer. Other malignancy. Unfit patients for chemotherapy.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}